Grail

Grail Assets per Share

The Total Assets per Share of Grail (GRAL) as of Oct 16, 2026 is 74.96 USD. In the previous year, Total Assets per Share was 76.53 USD — a change of -2.05% (lower).

Assets per Share

74.96USD

YoY

-2.05%

Last updated:

Total Assets per Share of Grail is 2025 74.96 USD. Total Assets per Share of Grail was 2024 76.53 USD. It decreases by -2.05% lower compared to the previous year.

The Grail Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
17.62 USD
Jan 1, 2019
16.30 USD
Jan 1, 2020
18.12 USD
Jan 1, 2021
249.82 USD
Jan 1, 2022
143.72 USD
Jan 1, 2023
116.90 USD
Jan 1, 2024
76.53 USD
Jan 1, 2025
74.96 USD
The Grail Assets per Share history
YEARAssets per ShareYoY
74.96USD-2.05%
76.53USD-34.53%
116.90USD-18.66%
143.72USD-42.47%
249.82USD+1,278.73%
18.12USD+11.14%
16.30USD-7.47%
17.62USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Grail Stock analysis

What does Grail do? Grail Inc, with ticker GRAL and ISIN US3847471014, is a US-based biotechnology company headquartered in Menlo Park. The company operates within the Health Care sector and has 910 employees. Grail Inc. went public on June 12, 2024. The company's website is https://www.galleri.com/. Grail Inc. focuses on early cancer detection through advanced technologies including next-generation sequencing, population-scale clinical studies, and machine learning. Its platform utilizes methylation-based approaches to support cancer screening and precision oncology, targeting multiple cancer types for early detection. The company's products include Galleri, a screening test for multi-cancer early detection, which helps guide healthcare decisions for cancer diagnosis. Grail Inc. aims to shift paradigms in cancer detection by identifying diseases at earlier stages, thereby alleviating the global burden of cancer. The company's approach integrates software, automation, and data analysis to enhance the continuum of care for cancer patients. Grail Inc. is engaged in developing solutions for cancer screening, risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring, and recurrence tracking. The company's work is centered on improving outcomes through early intervention and personalized treatment strategies. The focus on early detection aligns with efforts to reduce cancer mortality rates and improve patient survival rates globally. Grail Inc. operates with a technology-driven approach to revolutionize cancer care through innovative diagnostic tools and methodologies. Grail is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grail stock

Total Assets per Share of Grail is 74.96 USD in 2025.

Total Assets per Share of Grail changed from 76.53 USD to 74.96 USD, representing a -2.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Grail since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Grail

All Key Metrics — Grail